Promotores: Wim Jiskoot; Ferry Ossendorp

Can the conditioning paradigm be used for checkpoint inhibition cancer treatment?

Promotores: W. Jiskoot, F. Ossendorp

Researchers from Leiden University Medical Center (LUMC) and Netherlands Cancer Institute (NKI) have discovered how specialised immune cells can detect and remove cancers that are ‘invisible’ to the conventional defence mechanisms of the immune system. Their work has been published in Nature. The findings…

Leiden researchers have developed a groundbreaking model to advance cancer immunotherapy. Using a 3D printer, they create mini-tumors within an environment that closely mimics human tissue. They have also developed a method to monitor real-time interactions of these mini-tumours with immune cells during…

This thesis focuses on using liposomes in two different treatment strategies; vaccination (or immunotherapy) and delivery of a small molecule, and in two different disease models; cancer and atherosclerosis.

Promotores: J. Jonkers, K.E. de Visser

In order to be able to develop effective medicine and treatments to prevent or cure autoimmune diseases or cancer we need to understand the mechanisms how they arise and what drives their course.Unravelling the fundamental molecular mechanisms influencing the onset and course of diseases such as allergies,…

Atherosclerosis is a chronic inflammatory disease, and vaccination may be an attractive method to induce long lasting protection against endogenous factors that contribute to the development of atherosclerosis. We have shown that for example vaccination against modified LDL or interleukin-12 limits…

Cancer is still one of the most common diseases in the world. What exactly is cancer and will we one day be able to cure everyone? In a video from the Universiteit van Nederland Noel de Miranda (Tumour Immunology, LUMC) tells you about his research on new treatments.

The immune system plays a paradoxical role in the spread of breast cancer. Some immune cells contribute to metastasis, while other cells can be activated to strengthen the effect of chemotherapy. Kelly Kersten made this discovery in her PhD research. PhD defence 7 February.

For more information regarding ongoing research projects, please contact Prof. Johan Kuiper.

With cancer, a person’s body cells grow uncontrollably. Putting together a detailed picture of how this comes about makes it possible to develop efficient therapies. Researchers at the Leiden University Medical Centre (LUMC) and Leiden University are working together to gain a better understanding…

When internist Christian Blank made his very first discovery, his field of immunotherapy was the underdog of cancer research. Now, over 20 years later, Blank has been appointed Professor By Special Appointment of Internal Medicine for his clinical research into immunotherapy and will give his inaugural…

In this book liposomes are explored as delivery system for allergen-specific immunotherapy. Both cationic and anionic formulations are prepared with Bet v 1, one of the allergens in birch pollen.

Immunotherapies for cancer are an emerging class of therapeutic strategies which aim to treat cancer via augmentation of the immune system.

For effective cancer immunotherapy by vaccination, co-delivery of tumour antigens and adjuvants to dendritic cells and subsequent activation of antigen-specific cytotoxic T cells (CTLs) is crucial. In this study, a synthetic long peptide (SLP) harbouring the model CTL epitope SIINFEKL was encapsulated…

The objective of this study was to investigate the expression and function of GRHL2 in different breast cancer subtypes.

In this thesis, we aimed to better understand the underlying mechanisms involved in TNBC progression and metastasis formation and discover new targets to reduce breast cancer related deaths.

With cancer, the immune system is a double-edged sword: it can attack tumour cells, but can also help them grow and spread. It is a question of harnessing it. This is what Professor Karin de Visser argued in her inaugural lecture on 15 November 2019.

How can zebrafish research help to understand and fight human cancer?

Promotor: R.C.M. Pelger Co-Promotor: G. van der Pluijm

PhD defence

Some people are predisposed to develop cancer. Mutations in genetic material that increase a person’s chances of developing cancer can already be present at birth. Researchers are closely examining these mutations to learn more about how cancer begins to develop.

Strengthening a cancer patient's own immune system so that the body itself can better destroy cancer cells. This is at the heart of immunotherapy, the most promising progress in cancer treatment in recent years. In order to drive this development further, the Netherlands Cancer Institute-Antoni van…

Cancer represents a formidable current and future global health challenge. The LUMC medical research profile Cancer Pathogenesis and Therapy charges this challenge by developing and implementing innovative patient-tailored, multimodal diagnostic methods and treatment modalities.

We focus on a better understanding of the mechanisms of cancer drug resistance and metastasis.

In this research group, headed by Prof. Erik Danen, the aim is to unravel cellular signaling mechanisms in normal and diseased cells, with a long-standing interest in cell adhesion signaling. In complex multicellular organisms such as ourselves, a division of labor emerges where different tissues and…

ᅟ

The spindle-assembly checkpoint (SAC) is a safety mechanism which secures accurate chromosome segregation during mitosis.

Promotor: Prof.dr. B. van de Water, Co-promotor: E.H.J. Danen

In this research group, headed by Bob Van de Water, cell signaling programs that underlie adverse drug reactions as well as cancer development and progression are unraveled. Adverse drug reactions involve cell injury in critical target organ cells which leads to the activation of cellular stress response…

The clinical potential of applying synthetic lethality to cancer treatment is famously demonstrated by the BRCA1/PARP1 paradigm: a tumor specific defect in BRCA1 – a component of the DNA double-strand break (DSB) repair pathway homologous recombination (HR) – results in a remarkable sensitivity to PARP1…

Mechanisms fro drug resistance

Invasive lobular carcinoma (ILC) is the second most common type of breast cancer.

What distinguishes a tumour cell from a healthy cell? Researchers are trying to answer this question as precisely as possible. Certain differences could eventually lead to new therapies.

The molecular mechanisms that instigate a healthy cell to become malignant are fueled by (epi)genetic alterations in so-called driver genes.

Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by limited treatment options and unfavorable clinical outcomes. Therefore, the research described in this thesis focused on the exploration of novel targeted therapies for TNBC.

The main aim of this thesis was to unravel the signaling and regulatory networks that drive tumor cell migration during breast cancer metastasis.

Triple-negative breast cancer (TNBC) constitutes a small subtype (~15%) of breast cancer, but causes the majority of breast cancer-related deaths.

Cancer is the leading cause of death in the Netherlands, and, with over 100 different types of cancer, it’s not a simple disease. Today, skin, breast, lung, prostate and colon cancer are the most diagnosed forms. Therefore, the discovery and development of new drugs has the ability to significantly…

Exploiting metabolic vulnerabilities to identify anticancer compounds in zebrafish synthetic lethality screens.

The research described in this thesis focused on identifying novel drug targets and synergistic combinations for triple-negative breast cancer (TNBC), a virulent subtype of breast cancer with a dismal prognosis and limited therapeutic options.

In the hunt for a vaccine against cervical cancer, fundamental knowledge about the immune system and organic chemistry have been brought together and have already resulted in a vaccine that is now being tested in clinical trials. Scientists are now working hard on an improved variant.

In this thesis, we will utilize embryonic zebrafish tumour models to understand the interaction between engrafted human cancer cells and macrophages from the host, test drug administration modalities and anti-cancer efficacies of newly-developed PDT and PACT compounds, and test a light-triggered liposomal…

How to identify patients at risk of developing devastating, metastatic disease and facilitate the development of personalised treatment for prostate cancer patients?

In this thesis, we aim to shed light on the diverse and often opposing roles of integrin α3β1 in cancer.

Promotor: A.H. Meijer, Co-promotor: B.E. Snaar-Jagalska

The research within the Division of Cell Systems and Drug Safety, headed by Prof. Bob van de Water, is focused on novel therapeutic modalities and novel concepts in early drug discovery, in order to develop more effective and safer therapeutic strategies. We generate advanced cell and computational…

Promotor: E. Bouwman, Co-promotor: S. Bonnet